Pulmonary hypertension in idiopathic pulmonary fibrosis

Chest

Volumn 132, Issue 3, 2007, Pages 998-1006

  Patel, Nina M ^a   Lederer, David J ^b   Borczuk, Alain C ^a   Kawut, Steven M ^b  

^a Columbia University ^*  (United States)

^b NONE   (United States)

Author keywords

6 Min walk test; Idiopathic pulmonary fibrosis; Pulmonary artery pressure; Pulmonary hypertension

Indexed keywords

HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SURVIVAL RATE;

HUMANS; HYPERTENSION, PULMONARY; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SURVIVAL RATE;

EID: 35449003614     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.06-3087     Document Type: Article

References (62)

1. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:810-816
2. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150:967-972
3. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant 2006; 25:880-892
4. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129:746-752
5. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007; 175:875-880
6. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S-12S
7. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349
8. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171-1181
9. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128:2393-2399
10. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167:735-740
11. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131:657-663
12. Lederer DJ, Caplan-Shaw CE, O'Shea MK, et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006; 6:398-403
13. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233-238
14. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:659-664
15. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95:199-203
16. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99:675-691
17. Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005; 97:95-98
18. Hayes JA, Christensen TG, Gaensler EA. Myointimal plaques in pulmonary vascular sclerosis associated with interstitial lung fibrosis. Lab Invest 1979; 41:268-274
19. Heath D, Gillund TD, Kay JM, et al. Pulmonary vascular disease in honeycomb lung. J Pathol Bacteriol 1968; 95:423-430
20. Enson Y. Pulmonary heart disease: relation of pulmonary hypertension to abnormal lung structure and function. Bull N Y Acad Med 1977; 53:551-566
21. Colombat M, Mal H, Groussard O, et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38:60-65
22. Bignon J, Hem B, Molinier B. Morphometric and angiographic studies in diffuse interstitial pulmonary fibrosis. Prog Respir Res 1975; 8:141-160
23. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-1208
24. Renzoni EA, Walsh DA, Salmon M, et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003; 167:438-443
25. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963; 18:225-237
26. Tachihara A, Jin E, Matsuoka T, et al. Critical roles of capillary endothelial cells for alveolar remodeling in nonspecific and usual interstitial pneumonias. J Nippon Med Sch 2006; 73:203-213
27. Keane MP, Arenberg DA, Lynch JP III, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159:1437-1443
28. Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEB J 1994; 8:854-861
29. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin- 1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341:1550-1554
30. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:357-363
31. Said SI. Mediators and modulators of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291:L547-L558
32. Tuder RM, Cool C, Jennings C, et al Pulmonary vascular involvement in interstitial lung disease. In: Schwarz MI, King TE, eds. Interstitial lung disease. 3rd ed. London, UK: B.C. Decker, 1998; 251-263
33. Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6:359-365
34. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70:657-662
35. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170:360-365
36. Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996; 109:1566-1576
37. Weitzenblum E, Ehrhart M, Rasaholinjanahary J, et al. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 1983; 44:118-127
38. Chang JA, Curtis JR, Patrick DL, et al. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116:1175-1182
39. Nishiyama O, Taniguchi H, Kondoh Y, et al. Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. Respir Med 2007; 101:833-838
40. Doig JC, Corris PA, Hilton CJ, et al. Effect of single lung transplantation on pulmonary hypertension in patients with end stage fibrosing lung disease. Br Heart J 1991; 66:431-434
41. Globits S, Burghuber OC, Koller J, et al. Effect of lung transplantation on right and left ventricular volumes and function measured by magnetic resonance imaging. Am J Respir Crit Care Med 1994; 149:1000-1004
42. Harari S, Simonneau G, De Juli E, et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16:460-463
43. Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24:1269-1274
44. Bando K, Keenan RJ, Paradis IL, et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994; 58:1336-1342
45. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126:469-475
46. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-3111
47. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903
48. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123
49. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441-447
50. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin- A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049-2056
51. King TE, Behr J, Brown KK, et al. Bosentan use in idiopathic pulmonary fibrosis (IPF): results of the placebo-controlled BUILD-1 study [abstract]. Proc Am Thorac Soc 2006; 3:A524
52. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:56S-61S
53. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895-900
54. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160:600-607
55. Inhaled iloprost in adults with abnormal pulmonary pressure and associated with idiopathic pulmonary fibrosis. Clinical-Trials.gov #NCT00109681. Available at: http://clinicaltrials.gov. Accessed March 5, 2007
56. Maloney JP. Advances in the treatment of secondary pulmonary hypertension. Curr Opin Pulm Med 2003; 9:139-143
57. Sebkhi A, Strange JW, Phillips SC, et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003; 107:3230-3235
58. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157
59. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104:424-428
60. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131:897-899
61. Kinder BW, Collard HR, King TE Jr. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 2006; 130:302-303
62. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475-1482